Research and Markets (http://www.researchandmarkets.com/research/cl5psj/amyotrophic)
has announced the addition of GlobalData's new report "Amyotrophic
Lateral Sclerosis - Analysis and Market Forecasts to 2019" to their
Amyotrophic Lateral Sclerosis Lacks New and Effective Treatment Options
Amyotrophic Lateral Sclerosis (ALS) is the most common type of Motor
Neuron Disease (MND), yet the therapeutics market is woefully
inadequate, states a new report by healthcare experts GlobalData.
ALS, also known as Lou Gehrig's or Charcot disease, accounts for around
80% of all motor neuron cases worldwide. The progressive
neurodegenerative disease causes the impairment and eventual death of
the motor neurons in the spinal cord, brainstem, and motor cortex, which
are responsible for communication between the nervous system and
voluntary muscles. As motor neurons die, the brain loses the ability to
control muscle action, progressively hindering voluntary movement, with
patients in late stages of the disease sometimes becoming totally
paralyzed. Disease progression and patient survival varies, but only 10%
of those diagnosed with ALS live beyond a decade.
Patient numbers are set to rise, due to a growing elderly population and
inceasing disease awareness. Current treatment options are limited to
off-label medications that offer symptomatic relief, and Rilutek
(riluzole), the only approved disease-modifying treatment for ALS.
Rilutek has been shown to slow disease progress and improve survival in
ALS patients by three to four months, exhibiting disease-modifying
characteristics. However, while it allows patients more time in
higher-functioning states of the disease, it cannot cure the condition,
and its low efficacy and numerous side-effects have restricted its use.
Common side effects include nausea, dizziness, decreased lung function,
diarrhoea, pneumonia and vertigo. Around 14% of ALS patients who
received Rilutek in pre-marketing clinical trials discontinued treatment
due to adverse reactions. A high unmet need therefore remains for ALS
treatments with a novel mechanism of action which can alter disease
The ALS pipeline has a few late-stage therapies. Pipeline drugs that
could potentially launch in the forecast period include Avicena's ALS-02
(2015) and Mitsubishi Tanabe's Radicut (edaravone) (Japan only, 2013).
These products will expand the market, but will not transform the
treatment paradigm, as they will be mainly used as add-on treatments to
Rilutek. The most promising drug, Biogen's dexpramipexole, was
discontinued last month due to a lack of efficacy and improved survival
in phase III trial results. The anticipated patent expiry of Rilutek in
2013 will therefore act as a major barrier to market growth, due to the
lack of any upcoming therapeutics.
In 2011, the global ALS market was estimated at US$112m, but this value
is expected to decline at a negative Compound Annual Growth Rate (CAGR)
of 5.7% to hit an estimated US$70m by 2019.
This report is an essential source of information and analysis on the
global Amyotrophic Lateral Sclerosis Therapeutics market. It identifies
the key trends shaping and driving the market, and provides insights on
the prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders.
This report was built using data and information sourced from
proprietary databases, primary and secondary research, and in-house
analysis conducted by GlobalData's team of industry experts.
- Mitsubishi Tanabe Pharma
For more information visit http://www.researchandmarkets.com/research/cl5psj/amyotrophic.
[ Back To NFVZone's Homepage ]